United Therapeutics (NASDAQ:UTHR) CEO Sells $4,924,705.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $518.39, for a total value of $4,924,705.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $168,188,006.77. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Down 0.0%

NASDAQ UTHR traded down $0.24 during midday trading on Monday, hitting $512.88. The company had a trading volume of 291,650 shares, compared to its average volume of 489,537. The stock has a market cap of $22.00 billion, a price-to-earnings ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59. The firm has a fifty day simple moving average of $533.08 and a two-hundred day simple moving average of $537.80. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $6.41 earnings per share. As a group, equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Leuthold Group LLC increased its stake in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG boosted its position in shares of United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP grew its holdings in shares of United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares during the period. M&T Bank Corp grew its holdings in shares of United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after buying an additional 1,985 shares during the period. Finally, Seven Fleet Capital Management LP bought a new stake in shares of United Therapeutics in the 4th quarter valued at $633,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.